Evidence map›Paper›PMID 40732245›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Antimalarial Drug Repurposing of Epirubicin and Pelitinib in Combination with Artemether and Lumefantrine.

Douglas O Ochora, Reagan M Mogire, Bernard M Murithi, Farid Abdi, Erick N Ondari, Rael J Masai, Edwin Mwakio, Agnes Cheruyiot, Abiy Yenesew, Hoseah M Akala

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Douglas O OchoraDepartment of Biological Sciences, School of Pure and Applied Sciences, Kisii University, Kisii P.O. Box 408-40200, Kenya.ORCID 0000-0001-7406-7492
Reagan M MogireCenter for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20894, USA.ORCID 0000-0001-6454-1613
Bernard M MurithiMedical Biotechnology and Immunotherapy Research Unit, Department of Integrative Biomedical Sciences, Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town (UCT), Private Bag X3, Cape Town 7701, South Africa.
Farid AbdiKenya Medical Research Institute (KEMRI), Walter Reed Army Institute of Research-Africa, Kisumu P.O. Box 54-40100, Kenya.
Erick N OndariDepartment of Biological Sciences, School of Pure and Applied Sciences, Kisii University, Kisii P.O. Box 408-40200, Kenya.
Rael J MasaiDepartment of Biological Sciences, School of Pure and Applied Sciences, Kisii University, Kisii P.O. Box 408-40200, Kenya.
Edwin MwakioKenya Medical Research Institute (KEMRI), Walter Reed Army Institute of Research-Africa, Kisumu P.O. Box 54-40100, Kenya.ORCID 0000-0003-1193-1989
Agnes CheruyiotKenya Medical Research Institute (KEMRI), Walter Reed Army Institute of Research-Africa, Kisumu P.O. Box 54-40100, Kenya.
Abiy YenesewDepartment of Chemistry, Faculty of Science and Technology, University of Nairobi, Nairobi P.O. Box 30197-00100, Kenya.ORCID 0000-0002-1123-3200
Hoseah M AkalaKenya Medical Research Institute (KEMRI), Walter Reed Army Institute of Research-Africa, Kisumu P.O. Box 54-40100, Kenya.ORCID 0000-0001-8584-2706

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

artemetherdrug combinationdrug repurposingepirubicinlumefantrinemalariapelitinibPlasmodium falciparum

Identifiers

PMID40732245
PMCPMC12298365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.